Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Hydroxyurea (hydroxycarbamide), Aspirin, Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Essential thrombocythaemia (ET), Ruxolitinib and the tag mpn.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag mpn.
Shares A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU, A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV, Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients, PROUD-PV and CONTINUATION-PV.
Shares MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden, Hydroxyurea (hydroxycarbamide), Aspirin, Essential thrombocythaemia (ET).
Shares Low-PV, A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU, A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV, Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients.
The same record for scripts and assistants; checked 2026-09-16. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.